Nature Communications (Aug 2018)
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
- Ivana Zagorac,
- Sara Fernandez-Gaitero,
- Renske Penning,
- Harm Post,
- Maria J. Bueno,
- Silvana Mouron,
- Luis Manso,
- Manuel M. Morente,
- Soledad Alonso,
- Violeta Serra,
- Javier Muñoz,
- Gonzalo Gómez-López,
- Jose Francisco Lopez-Acosta,
- Veronica Jimenez-Renard,
- Albert Gris-Oliver,
- Fatima Al-Shahrour,
- Elena Piñeiro-Yañez,
- Jose Luis Montoya-Suarez,
- Juan V. Apala,
- Amalia Moreno-Torres,
- Ramon Colomer,
- Ana Dopazo,
- Albert J. R. Heck,
- Maarten Altelaar,
- Miguel Quintela-Fandino
Affiliations
- Ivana Zagorac
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Sara Fernandez-Gaitero
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Renske Penning
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University
- Harm Post
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University
- Maria J. Bueno
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Silvana Mouron
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Luis Manso
- Medical Oncology
- Manuel M. Morente
- Biobank, CNIO – Spanish National Cancer Research Center
- Soledad Alonso
- Pathology Department, Hospital Universitario de Guadalajara
- Violeta Serra
- Experimental Therapeutics Group, VHIO - Vall d’Hebron Institute of Oncology
- Javier Muñoz
- Proteomics Unit, CNIO – Spanish National Cancer Research Center
- Gonzalo Gómez-López
- Bioinformatics Unit, CNIO – Spanish National Cancer Research Center
- Jose Francisco Lopez-Acosta
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Veronica Jimenez-Renard
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Albert Gris-Oliver
- Experimental Therapeutics Group, VHIO - Vall d’Hebron Institute of Oncology
- Fatima Al-Shahrour
- Bioinformatics Unit, CNIO – Spanish National Cancer Research Center
- Elena Piñeiro-Yañez
- Bioinformatics Unit, CNIO – Spanish National Cancer Research Center
- Jose Luis Montoya-Suarez
- Medical Oncology, Hospital Nacional Guillermo Almenara Irigoyen – ESSALUD
- Juan V. Apala
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- Amalia Moreno-Torres
- Pathology Department, Hospital Universitario de Fuenlabrada
- Ramon Colomer
- Medical Oncology, Hospital La Princesa
- Ana Dopazo
- Genomics Unit, CNIC - Spanish National Center for Cardiovascular Research
- Albert J. R. Heck
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University
- Maarten Altelaar
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University
- Miguel Quintela-Fandino
- Breast Cancer Clinical Research Unit, CNIO – Spanish National Cancer Research Center
- DOI
- https://doi.org/10.1038/s41467-018-05742-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Triple-negative breast cancer (TNBC) lacks prognostic and predictive markers. Here, the authors use phosphoproteomics to define kinases with distinct activity profiles in TNBC, demonstrating their prognostic value as well as their utility for simplifying TNBC classification and designing drug regimens.
